Postsynaptic 5-hydroxytryptamine(1A) receptor activation increases in vivo dopamine release in rat prefrontal cortex
by
Sakaue M, Somboonthum P, Nishihara B,
Koyama Y, Hashimoto H, Baba A, Matsuda T
Laboratory of Molecular Neuropharmacology,
Graduate School of Pharmaceutical Sciences,
Osaka University,
1-6 Yamado-oka, Suita, Osaka 565-0871 Japan.
Laboratory of Medicinal Pharmacology,
Graduate School of Pharmaceutical Sciences,
Osaka University,
1-6 Yamado-oka, Suita,
Osaka 565-0871 Japan.
Br J Pharmacol 2000 Mar 5; 129(5):1028-1034

ABSTRACT

5-Hydroxytryptamine (5-HT) plays a role in the regulation of 3,4-dihydroxyphenylethylamine (dopamine) neurons in the brain, but the precise mechanism of regulation by 5-HT(1A) receptors of dopamine release has not been defined. The present study describes the effect of 5-{3-[[(2S)-1,4-benzodioxan-2ylmethyl]amino]propoxy}-1,3-benzodioxole HCl (MKC-242), a highly potent and selective 5-HT(1A) receptor agonist, on dopamine release in the prefrontal cortex using microdialysis in the freely moving rat. Subcutaneous injection of MKC-242 (0.3 - 1.0 mg kg(-1)) increased extracellular levels of dopamine in the prefrontal cortex. The effect of MKC-242 in the prefrontal cortex was antagonized by pretreatment with the selective 5-HT(1A) receptor antagonist, N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-(2-pyridinyl)cyclohexanecarboxamide (WAY100635; 1 mg kg(-1), i.p.). Local application of WAY100635 (10 muM) via a microdialysis probe antagonized the effect of systemic MKC-242 in an increasing dopamine release, and locally infused 8-hydroxy-2-(di-n-propylamino)tetralin (10 muM) increased dopamine release in the prefrontal cortex. MKC-242 increased cortical dopamine release in the rats pretreated with 5,7-dihydroxytryptamine (150 mug, i.c.v.) that caused an almost complete reduction in cortical 5-HT content. The effect of MKC-242 to increase dopamine release was also observed in the hippocampus, but not in the striatum or nucleus accumbens. Fluoxetine, a selective serotonin reuptake inhibitor, increased dopamine release in the prefrontal cortex, but not in the nucleus accumbens, while buspirone, a 5-HT(1A) receptor agonist, increased dopamine release in both brain regions. The present results indicate that activation of postsynaptic 5-HT(1A) receptors increases dopamine release in a brain region-specific manner.

TCAs
SSRIs
5-HT2
5-HT3
5-HT1a
5-HT1b
Buspirone
Mirtzapine
Flibanserin
Imipramine
Neuroleptics
5-HT2c/5-HT2b
MDMA and 5-HT1a
Suicide and 5-HT1a
5-HT1a and F11440

Refs
and further reading

HOME
HedWeb
Nootropics
cocaine.wiki
Future Opioids
BLTC Research
MDMA/Ecstasy
Superhapiness?
Utopian Surgery?
The Abolitionist Project
The Hedonistic Imperative
The Reproductive Revolution
Critique of Huxley's Brave New World

The Good Drug Guide
The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family